Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges [PDF]
BiomedicinesModulation of immune response to target tumor cells has been shown to be a successful strategy for cancer treatment. Over the past years immunotherapy has been integrated into cancer treatment and PD-1 blockers have become the backbone of treatment ...
Anand Rotte +2 more
doaj +2 more sources
The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1 [PDF]
OncoImmunology, 2018 Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has
Lisa Derosa +3 more
doaj +2 more sources
Role of immune checkpoint blockers in patients with EGFR mutation. [PDF]
Transl Lung Cancer Res, 2018 Ward J, Morgensztern D.
europepmc +4 more sources
Emerging Therapeutic Agents for Colorectal Cancer
Molecules, 2021 There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC’s therapeutic agents that have shown the potential for progress in clinical practice.
Marianna Nalli +4 more
doaj +1 more source
A tumor-targeted immune checkpoint blocker [PDF]
Proceedings of the National Academy of Sciences, 2019 Significance Current immune checkpoint inhibitors are not tumor specific and induce systemic immune activation in other tissues and organs. Combination immunotherapies further amplify these toxicities, which limit their clinical application.
Yuhan, Zhang +11 more
openaire +2 more sources
Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers [PDF]
Clinical and Experimental Immunology, 2020 Summary Immune checkpoint blockers improve the overall survival of a limited number of patients among different cancers. Identifying pathways that influence the immunological and clinical response to treatment is critical to improve the therapeutic efficacy and predict clinical responses.
M Segovia +4 more
openaire +3 more sources
Frontiers in Oncology, 2022 Cervical cancer is one of the women-associated tumors that affects numerous people yearly. It is the fourth most common malignancy in women worldwide.
Haigang Ding +9 more
doaj +1 more source
Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
OncoImmunology, 2023 Checkpoint blockade immunotherapy transforms many types of cancer; however, in the field of metastatic colorectal cancer, checkpoint blockers are only effective in microsatellite-unstable tumors, which represent only a minority of patients ...
Marion Thibaudin, Francois Ghiringhelli
doaj +1 more source
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology [PDF]
, 2020 Combination immunotherapy (CIT) is currently applied as a treatment for different cancers and is proposed as a cure strategy for chronic viral infections. Whether such therapies are efficient during an acute infection remains elusive.
Akhmetzyanova, Ilseyar [u.v.m.] +9 more
core +1 more source
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers [PDF]
Clinical Cancer Research, 2016 Abstract Immunotherapy is currently transforming cancer treatment. Notably, immune checkpoint blockers (ICB) have shown unprecedented therapeutic successes in numerous tumor types, including cancers that were traditionally considered as nonimmunogenic. However, a significant proportion of patients do not respond to these therapies. Thus,
Roman M, Chabanon +5 more
openaire +2 more sources